Stock Track | Syndax Pharmaceuticals Soars 5.01% as Multiple Analysts Reiterate Buy Ratings and Raise Price Targets

Stock Track11-04

Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company, which focuses on developing innovative cancer therapies, has captured the attention of several major financial institutions.

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, while H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating with a price target of $40.00. Additionally, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, keeping an Overweight rating on the shares.

These bullish sentiments from analysts suggest growing confidence in Syndax Pharmaceuticals' strategic advancements and growth potential. While specific details about the company's recent developments were not provided, the unanimous positive outlook from multiple financial institutions appears to be driving investor enthusiasm. As the company continues to progress in its cancer therapy research and development, market participants will likely keep a close eye on Syndax's future announcements and clinical trial results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147724717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 23:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147724717","market":"sg","top_or_hot":-1,"title":"Stock Track | Syndax Pharmaceuticals Soars 5.01% as Multiple Analysts Reiterate Buy Ratings and Raise Price Targets","media":"Stock Track","content":"<p>Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company, which focuses on developing innovative cancer therapies, has captured the attention of several major financial institutions.</p>\n\n<p>Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, while H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating with a price target of $40.00. Additionally, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, keeping an Overweight rating on the shares.</p>\n\n<p>These bullish sentiments from analysts suggest growing confidence in Syndax Pharmaceuticals' strategic advancements and growth potential. While specific details about the company's recent developments were not provided, the unanimous positive outlook from multiple financial institutions appears to be driving investor enthusiasm. As the company continues to progress in its cancer therapy research and development, market participants will likely keep a close eye on Syndax's future announcements and clinical trial results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Syndax Pharmaceuticals Soars 5.01% as Multiple Analysts Reiterate Buy Ratings and Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Syndax Pharmaceuticals Soars 5.01% as Multiple Analysts Reiterate Buy Ratings and Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company, which focuses on developing innovative cancer therapies, has captured the attention of several major financial institutions.</p>\n\n<p>Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, while H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating with a price target of $40.00. Additionally, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, keeping an Overweight rating on the shares.</p>\n\n<p>These bullish sentiments from analysts suggest growing confidence in Syndax Pharmaceuticals' strategic advancements and growth potential. While specific details about the company's recent developments were not provided, the unanimous positive outlook from multiple financial institutions appears to be driving investor enthusiasm. As the company continues to progress in its cancer therapy research and development, market participants will likely keep a close eye on Syndax's future announcements and clinical trial results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"","article_id":"1147724717","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147724717","pubTimestamp":1762270853,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"个股追踪|Syndax Pharmaceuticals大涨5.01%多位分析师重申买入评级并上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"Syndax Pharmaceuticals (SNDX) saw its stock soar 5.01% in Tuesday's pre-market trading session, following a series of positive analyst reports and price target upgrades. The biotechnology company, which focuses on developing innovative cancer therapies, has captured the attention of several major financial institutions.\nBank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, while H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating with a price target of $40.00. Additionally, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, keeping an Overweight rating on the shares.\nThese bullish sentiments from analysts suggest growing confidence in Syndax Pharmaceuticals' strategic advancements and growth potential. While specific details about the company's recent developments were not provided, the unanimous positive outlook from multiple financial institutions appears to be driving investor enthusiasm. As the company continues to progress in its cancer therapy research and development, market participants will likely keep a close eye on Syndax's future announcements and clinical trial results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147724717","isCrawlerRequest":true}